Search
Dexibuprofen
go.drugbank.com/drugs/DB09213ApprovedWithdrawnFor Metabolism, Enzymes, Carriers, Transporters Sections, refer to [Ibuprofen].
Phentermine
go.drugbank.com/drugs/DB00191ApprovedIllicitInvestigational[A174367] Phentermine was FDA approved for short-term weight management in 1959 and it became widely used in 1960.
Categories: Monoamine Oxidase A Inhibitors for interaction with Monoamine Oxidase A substratesAbaloparatide
go.drugbank.com/drugs/DB05084ApprovedInvestigational[L740] In October 2022, the EMA's Committee for Medicinal Products for Human Use (CHMP) recommended abaloparatide be granted marketing authorization in Europe [L43552] and the drug was fully authorized … [L740] It was first approved by the FDA on April 28, 2017,[A256748] for the treatment of osteoporosis in postmenopausal women and is also used to increase bone density in men with osteoporosis.
Indomethacin
go.drugbank.com/drugs/DB00328ApprovedInvestigationaleffect of indometacin is not fully understood, however, it is thought to be mediated through potent and nonselective inhibition of the enzyme cyclooxygenase (COX), which is the main enzyme responsible for … Indometacin was first discovered in 1963 and it was first approved for use in the U.S. by the Food and Drug Administration in 1965, [A486] along with other acetic acid derivatives such as [diclofenac]
Categories: Topical Products for Joint and Muscular Pain, Antiinflammatory Preparations, Non-Steroids for Topical UseMetamfetamine
go.drugbank.com/drugs/DB01577ApprovedIllicitInvestigationalWithdrawnIt is a scheduled drug in most countries due to its high potential for addiction and abuse. … The FDA withdrew its approval for the use of all parenteral drug products containing methamphetamine hydrochloride, a metamfetamine salt.[L43942]
Categories: Psychostimulants, Agents Used for ADHD and Nootropics, Monoamine Oxidase A Inhibitors for interaction with Monoamine Oxidase A substratesTivozanib
go.drugbank.com/drugs/DB11800ApprovedInvestigationalMarketed by Aveo Oncology, tivozanib is a promising therapy for individuals with RCC who have not been treated successfully with other therapies.[L32524] … Renal cell carcinoma (RCC) is responsible for 3% of cancer cases[A231314] and is one of the 10 most common cancers in adults. The average age of diagnosis is between age 65 to 74.
Categories: Vascular endothelial growth factor receptor (VEGFR) tyrosine kinase inhibitorsThiabendazole
go.drugbank.com/drugs/DB00730ApprovedVet approvedWithdrawnIt is active against a variety of nematodes and is the drug of choice for strongyloidiasis. It has CNS side effects and hepatototoxic potential.
Categories: Antifungals for Topical Use, Antifungals for Dermatological UseDenileukin diftitox
go.drugbank.com/drugs/DB00004ApprovedInvestigationalDenileukin diftitox is an IL2-receptor-directed cytotoxin, is a recombinant DNA-derived fusion protein composed of the amino acid sequences for diphtheria toxin fragments A and B (Met<sub>1</sub>-Thr<sub … >387</sub>)-His and the sequence for human interleukin-2 (IL-2; Ala<sub>1</sub>-Thr<sub>133</sub>).
Somatrogon
go.drugbank.com/drugs/DB14960ApprovedInvestigational[A241515] Recombinant growth hormone therapy for growth hormone deficiency and other conditions has been available since 1985, with daily administration being the standard treatment for many years. … [L39060] In June 2023, the FDA approved the use of somatrogon also for the treatment of pediatric growth hormone deficiency.
Flurpiridaz F-18
go.drugbank.com/drugs/DB18773ApprovedFlurpiridaz F-18 is a radioactive diagnostic drug indicated for positron emission tomography (PET) myocardial perfusion imaging (MPI), which is an imaging process used in patients with known or suspected